A retrospective analysis of data from 73 consecutive patients with toxic multinodular goitre treated with iodine-131 ( 131 I) during a 2-year period was performed to investigate if serum TSH at the time of 131 I treatment influences the outcome. The dose of 131 I was calculated according to a model compensating for thyroid size estimated by palpation and 24-h 131 I uptake. Serum TSH was determined by a third-generation assay with a functional sensitivity of 0.03 mU/l. A significantly more pronounced response to 131 I treatment was observed in patients with TSH > 0.0 mU/l than in patients with TSH=0.0 mU/l (P ¼ 0.0006). This difference resulted in a threefold lower frequency of non-responders and a fivefold higher rate of early hypothyroidism in the group with detectable serum TSH. While the high frequency of hypothyroidism among patients with measurable serum TSH can be explained by destruction of normal thyroid tissue, the high frequency of treatment failure in the group with serum TSH ¼ 0.0 mU/l suggests that autonomous thyroid tissue may also be sensitized to a deleterious effect of 131 I through stimulation by TSH. We conclude that serum TSH has a significant influence on the outcome of 131 I treatment of toxic multinodular goitre. The results of 131 I treatment may be improved by adjustment of the dose of 131 I according to the serum TSH level, in addition to adjustment for goitre size and 24-h 131 I uptake.
Introduction
Iodine-131 ( 131 I) is effective in the treatment of toxic multinodular goitre. A significant disadvantage of this therapeutic approach is the variable response, which results in a relatively high frequency of treatment failure, and in overtreatment (1) . Much effort has been devoted to the improvement of 131 I dosage by the development of compensatory models that take into account goitre volume and thyroid iodine uptake (2, 3) . However, many centres still report treatment failure rates of 5-70% for nodular goitres and development of hypothyroidism in 5-47% of patients, depending on the 131 I dosage schedule and treatment policy (4) (5) (6) (7) (8) (9) (10) . Even with more accurate determination of goitre volume (11) or of measure of thyroid iodine metabolism (12, 13) , it seems difficult to achieve better results.
At present, the factors responsible for the variable effect of 131 I treatment are poorly clarified. One study of solitary toxic nodules, which partially applied less sensitive thyrotrophin (TSH) assays in a limited number of patients, indicated that a suppressed serum TSH concentration at the time of 131 I treatment may diminish the risk of development of hypothyroidism (13) . This was explained by a reduction of iodine uptake in the extranodular normal tissue (13) . A similar hypothesis regarding serum TSH and iodine uptake in normal thyroid tissue could be proposed for multinodular toxic goitres. The development of new highly sensitive radioimmunoassays for TSH has provided the opportunity to test this hypothesis more thoroughly.
The aim of the present study was to investigate if the presence of a detectable serum concentration of TSH influences the outcome of 131 I treatment of toxic multinodular goitre in patients pretreated with antithyroid drugs.
Methods

Patients
After approval was given by the regional ethics committee, the records of 154 consecutive patients treated with 131 I in 1993 and 1994 in our department were reviewed with regard to data concerning their last 131 I treatment in the period. A diagnosis of toxic multinodular goitre was based on the results of a 99m technetium thyroid scan, serum TSH concentration and indices of free tri-iodothyronine (T 3 ) and thyroxine (T 4 ). We included in the analysis only those patients fulfilling the following criteria: 1) documented hyperthyroidism (TSH ¼ 0.0 mU/l and increased indices of free T 3 or T 4 , TSH ¼ 0.0 mU/l by two determinations with an interval of at least 1 month, or patients treated with antithyroid agents at referral); 2) pretreatment with antithyroid agents before 131 I treatment; 3) follow-up of at least 12 months after 131 I treatment. Six patients who were euthyroid, 28 patients with diffuse toxic goitre, 26 with solitary toxic nodule and two for whom the 99m technetium thyroid scan was missing were excluded from the study. Six patients with toxic multinodular goitre who did not receive antithyroid medication before 131 I treatment, two patients followed for less than 12 months, and two patients lost to follow-up were likewise excluded. Because our licence for 131 I treatment permits a maximum dose of 600 MBq per treatment, a further eight patients calculated to have received doses exceeding this limit were also excluded. Finally, one patient for whom the TSH determination at the time of 131 I treatment was missing was excluded from the study.
Seventy-three patients with toxic multinodular goitre were finally included in the study. Table 1 gives details of their age, sex, thyroid mass estimated by palpation, serum TSH, free T 3 and T 4 indices at referral and at the time of 131 I treatment, previous thyroid surgery or 131 I treatment, type of antithyroid pretreatment (carbimazole or propylthiouracil (PTU)), dose of 131 I, duration of follow-up, and thyroid function.
At follow-up patients with serum TSH concentrations of 0.1-4.0 mU/l and who had discontinued thyroid medication were considered to be euthyroid. Patients with serum TSH 0.0 mU/l and those receiving antithyroid drugs (including additional 131 I treatment or thyroid surgery) were registered as non-responders, whereas patients with serum TSH concentrations greater than 4.0 mU/l and those receiving L-thyroxine were classified as hypothyroid.
I treatment schedule
After blood samples had been drawn for the estimation of serum TSH, T 4 , T 3 and T 3 uptake, a test dose of 1 MBq 131 I was given by mouth. The 24-h 131 I uptake was measured and the size of the goitre was estimated by a single endocrinologist. The results of the hormonal analyses were not available until after the treatment with 131 I; consequently, evaluation of the size of the goitre was performed blind to the serum TSH values. The dose of 131 I was calculated according to the formula:
Weight of goitre (g) × 5.55 MBq 24-h 131 I uptake
Patients discontinued antithyroid medication from 4 days before to 4 days after treatment with 131 I and were followed in the outpatient clinic after 2 and 4 months and thereafter at 4-month intervals.
Laboratory analyses
Serum hormone concentrations were estimated by commercial assays: serum TSH (LUMI-test, Brahms Diagnostica GMBH, Berlin, Germany); serum T 4 (Amerlex-M T 4 RIA, Johnson & Johnson Clinical Diagnostics Ltd, Rochester, NY, USA); serum T 3 and T 3 uptake (Coat-ACount, Diagnostic Products Corporation, Los Angeles, CA, USA). Free T 4 and free T 3 indices were calculated as the product of the T 3 uptake and serum T 4 or serum T 3 respectively.
The assay for serum TSH (LUMI-test) is a so-called third-generation assay based on the immunoluminometric principle. The functional sensitivity is 0.03 mU/l. However, the results from our laboratory are reported to only one decimal place -i.e. serum concentrations less than 0.05 mU/l are reported as 0.0 mU/l.
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Statistics
Results are shown as mean with standard deviation. Differences in clinical parameters between two groups of patients were tested with a two-sample rank sum test (Mann-Whitney test) and differences between more than two groups were analysed by the Kruskal-Wallis test. The analyses were performed using MEDSTAT, version 2.12 (Wulff HR and Schlichting P 1991, ASTRA Group A/S, Denmark). A two-tailed P-value less than 0.05 was considered significant.
Results
Impact of serum TSH on outcome
The outcome after 131 I treatment of patients with multinodular toxic goitre is shown in Table 2 . After a mean follow-up of 20.5 months, 51% of the patients were euthyroid, 16% had developed hypothyroidism, and 33% remained hyperthyroid. A significantly more pronounced response was observed in the subgroup with detectable serum TSH than in the subgroup with serum TSH ¼ 0.0 mU/l (P ¼ 0.0006, Mann-Whitney). A total of 22% of the patients with detectable serum TSH became hypothyroid compared with only 4% of those with suppressed serum TSH. The rate of treatment failure among patients with detectable TSH was 20%, compared with a rate of 61% in the group with suppressed TSH.
The clinical characteristics of the patients with either suppressed or detectable TSH levels are shown in Table  1 . No difference was observed between the two groups as regards age, sex, frequency of previous surgery or of 131 I treatment, type of antithyroid drug, goitre weight, 131 I dosage, 24-h 131 I uptake or duration of follow-up. As would be expected, the indices of free T 3 and T 4 were significantly greater in the patients with undetectable serum TSH (P < 0.00001 and P ¼ 0.0001 respectively; Mann-Whitney). Table 3 shows the clinical characteristics according to outcome. The goitre volume differed significantly between the three subgroups (P=0.0006, KruskalWallis), with a considerably smaller goitre volume in the hypothyroid group. Because the 24-h 131 I uptake was the same in the three groups, a similar pattern with regard to the 131 I dose was also observed (P ¼ 0.0008, Kruskal-Wallis).
Impact of other factors on outcome
As shown in Fig. 1 , the patients could be categorized into four subgroups according to their serum TSH (¼0.0 mU/l or >0.0 mU/l) and goitre size (Յ30 g or > 30 g), with significantly different response profiles (P ¼ 0.02, Kruskal-Wallis). The optimal response pattern was present in the subgroup with detectable serum TSH and large goitres. There was a very high proportion EUROPEAN of non-responders (63%) among the patients with suppressed TSH and large goitres. Conversely, the rate of hypothyroidism was high in the subgroup with detectable TSH and small goitres (54%). There was no difference between non-responders, euthyroid or hypothyroid patients as regards age, sex, the frequency of previous surgery or 131 I treatment (Table 3) , and no significant difference between the three groups as regards type of antithyroid treatment. However, there was a tendency towards an increasing frequency of pretreatment with PTU (and decreasing frequency of pretreatment with carbimazole) and increasing response to 131 I. The PTU-treated group had significantly smaller goitre weights than the carbimazole-treated group (37.1 g and 49.9 g respectively, P ¼ 0.004; Mann-Whitney).
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Discussion
No study on the relationship between serum TSH and outcome of 131 I treatment of toxic multinodular goitre has been published in the literature. This is probably a reflection of the long era of relatively insensitive TSH assays, which has recently been ended by development of new, ultrasensitive third-generation RIAs. Because almost all hyperthyroid patients have undetectable serum concentrations of TSH in our assay, we assume that a serum TSH value of 0.0 mU/l is associated with the absence of TSH, or at most the presence of negligible amounts. This study has demonstrated that, among patients with multinodular toxic goitre, a serum concentration of TSH 0.05 mU/l or more at the time of 131 I treatment is associated with a more pronounced therapeutic response, resulting in a twofold higher response rate at the expense of a high frequency of early myxoedema. This observation was not explained by differences in the size of goitre, dose of 131 I, or 24-h 131 I uptake, or by differences in any of the other clinical parameters analysed in the two groups of patients (Table 1) .
Hypothetically, a selective, complete destruction of all autonomous tissue would leave the patient euthyroid. Thus the greater incidence of myxoedema in the group of TSH-stimulated patients is probably explained by an unwanted effect of 131 I on the normal thyroid tissue. In contrast, the greater frequency of non-responders among patients with suppressed levels of TSH was unexpected. As treatment failure is exclusively due to an insufficient effect of 131 I on the autonomous tissue, this observation suggests that the effect of 131 I on autonomous thyroid tissue, also, can be enhanced through stimulation by TSH.
The different effects of 131 I are obviously independent of thyroid 24-h iodine uptake; however, this does not exclude a difference in effective half-life of 131 I as a possible explanation of our observations (12) .
Pretreatment with PTU or carbimazole has been reported to exert a radioprotective effect on the thyroid (14, 15) . Because these drugs will tend to increase serum TSH, this effect must be independent of TSH. The non-significantly increased frequency of PTU-treated patients among cases with the most pronounced response to 131 I is probably explained by the smaller goitre size among these patients, rather than by a difference in the radioprotective effect.
In agreement with the findings of previous investigations (15) , our study indicates a more pronounced response of patients with small goitres. This may be explained by a larger radiation dose to all parts of the gland, or by a systematic overestimation of the volume of small goitres. The palpatory evaluation of goitre size is inaccurate (16) . However, a more precise determination of the goitre size by ultrasonography did not lead to improved results of 131 I treatment (11) . In the present study, palpation was performed by a single, experienced endocrinologist, who was blinded to the TSH value. Thus a systematic bias with influence on the interpretation of the impact of serum TSH on the outcome is excluded.
Given that the aim of 131 I treatment still is to achieve the highest response rate and the lowest rate of hypothyroidism possible, the results of the present study may imply the need for an altered treatment strategy. With knowledge of the serum TSH value in addition to the goitre volume and 131 I uptake, it would be possible to identify, before their treatment, a number of patients at high risk of an adverse response to the present schedule for 131 I treatment. Consequently, their schedule might be adjusted. In patients with small goitres of 30 g or less and measurable serum TSH, 131 I dosage should be reduced to avoid hypothyroidism. In contrast, in those with large goitres and suppressed serum TSH, the dosage should be increased to achieve the highest possible response rate. Assuming that the patients with detectable serum TSH and large goitres represent those likely to have the best obtainable response profile, we estimate that the rate of treatment failure could be reduced from 33% to 23%, and that of early hypothyroidism from 16% to 8%.
The present demonstration of the influence of serum TSH on the outcome of 131 I treatment of toxic multinodular goitre requires confirmation by prospective studies.
